ClinicalTrials.gg
RecruitingNCT07220772Updated Nov 12, 2026

A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults

A Phase 3 interventional study of Mibavademab in Monogenic Obesity, sponsored by Regeneron Pharmaceuticals. Recruiting at 4 sites in 3 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 12, 2026First sites in Turkey (Türkiye) and Spain3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies in Obesity, Morbid with a site in Turkey — 8 open to participants now, 8 under way, 1 of them phase 3. Obesity, Morbid · Turkey.

Planned enrollment
37th of 38
4 · median 66
Started
2026
with 4 others
Phase 3
Only one
of the 70
Registered
57th of 70
by date

Among the 70 studies in Obesity, Morbid with a site in Turkey, this one is the 37th largest by planned enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2026, is the only one in phase 3, and was the 57th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 163 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

8 of the 70 studies in Obesity, Morbid with a site in Turkey are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 110 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 84 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Obesity, Morbid with a site in Turkey, or all of them as a file.
02

Study summary

This study is researching an experimental drug called mibavademab. The study is focused on patients with a condition called monogenic obesity. Monogenic obesity is caused by a change in the leptin gene that keeps it from working properly. This causes the body to not be able to feel full or control feelings of hunger.

The aim of the study is to see how well mibavademab controls the body weight and how safe it is.

The study is looking at several other research questions, including:

  • How much mibavademab is in the blood at different times
  • Whether the body makes proteins called antibodies against mibavademab (which could stop mibavademab from working as well or could lead to side effects)
  • What side effects may happen from taking mibavademab
03

Conditions studied

  • Monogenic Obesity

Browse trials for

Keywords

  • Biallelic loss of function variants of the LEP gene mutations
  • Leptin deficiency
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Has documented medical history of biallelic loss of function variants of the LEP gene prior to the screening visit
  2. Has class ≥2 obesity at screening and at baseline, as defined in the protocol

Key Exclusion Criteria:

  1. Unwilling or unable to provide, or have the treating physician provide, documented historical weight for at least 6 months prior to screening
  2. History of bariatric surgery within approximately the past 12 months of study screening
  3. History of weight loss of ≥5% of body weight in approximately the past 3 months of study screening
  4. History of genetic causes of obesity other than/in addition to biallelic loss of function variants of the LEP gene
  5. History of schizophrenia, bipolar disorder, or other mental illness that, in the opinion of the investigator, might pose a safety risk to participation in a clinical study of an drug
  6. Any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) during screening or baseline, or any lifetime history of a suicide attempt, or any lifetime history of suicidal behavior, including ideation
  7. Treatment with medications for weight loss or medications with known side effects of weight loss within the past approximately 3 months of study screening
  8. Participants currently being treated with metreleptin, or a history of prior treatment with metreleptin as defined in the protocol

NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (estimated)

Study arms

  • Experimental
    Mibavademab

    Drug: Mibavademab

Interventions

  • Administered as per the protocol

    Also known as: REGN4461

06

What researchers measure

Primary outcomes

  1. Percent change in Body Mass Index (BMI)

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Percent change in BMI

    Time frame: Baseline to Week 52

  2. Absolute change in BMI

    Time frame: Baseline, Through Week 52

  3. Percent change in body weight

    Time frame: Baseline, Through Week 52

  4. Absolute change in body weight

    Time frame: Baseline, Through Week 52

  5. Change in waist circumference

    Participants aged ≥18 years

    Time frame: Baseline, Through Week 52

  6. Change in absolute total fat mass by whole body DXA

    Time frame: Baseline, Through Week 52

  7. Change in percent total fat mass by whole body DXA

    Time frame: Baseline, Through Week 52

  8. Change in absolute regional fat mass by whole body DXA

    Time frame: Baseline, Through Week 52

  9. Change in percent regional fat mass by whole body DXA

    Time frame: Baseline, Through Week 52

  10. Change in scores in the symptoms of hyperphagia questionnaire

    Symptoms of Hyperphagia - Caregiver Version© is completed by a caregiver. Symptoms of Hyperphagia - Patient Version© is completed by the participants who are aged \<12 years or for participants who are unable to self-complete. The questionnaires both assesses the frequency of hunger symptoms on a categorical scale (Never, 1 or 2 times, 3 or more times) over the past 24 hours and are scored combining the total scores across the items. Higher scores indicate greater severity.

    Time frame: Baseline, Through Week 52

  11. Change in scores in the impacts of hyperphagia questionnaire

    For participants who are aged \<12 years or for participants who are unable to self-complete, the Impacts of Hyperphagia - Caregiver Version© is completed by a caregiver. For participants aged ≥12 years who are able to self-report, the Impacts of Hyperphagia - Patient Version© is completed by the participant. Both questionnaires assess the impact of hyperphagia on a categorical scale (range: not at all, a little, moderately, a great deal). The participant version is scored using a total score across the 5 items. The caregiver version is scored separately for each section. Higher scores indicate a greater impact of hyperphagia.

    Time frame: Baseline, Through Week 52

  12. Change in scores in the hunger questionnaire

    The Daily Hunger Assessment is a daily, single item measuring hunger for participants aged ≥12 years who are able to self-complete, participants are asked to rate their highest level of hunger over for the day, where "0" is "not hungry at all" to "10" the hungriest possible."

    Time frame: Baseline, Through Week 52

  13. Number of treatment-emergent adverse events (TEAEs)

    Time frame: Through Week 65

  14. Severity of TEAEs

    Time frame: Through Week 65

  15. Concentrations of total mibavademab in serum

    Time frame: Through Week 65

  16. Incidence of anti-drug antibody (ADA) to mibavademab

    Time frame: Through Week 65

  17. Titer of ADA to mibavademab

    Time frame: Through Week 65

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2025
First posted
Oct 24, 2025
StartActual
Feb 9, 2026
Primary completionEst.
Jun 18, 2027
CompletionEst.
Apr 21, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added — first sites in Turkey (Türkiye) and Spain
Show 3 added (2 Turkey (Türkiye), 1 Spain)
  • Erciyes University · Kayseri, Turkey (Türkiye)
  • Ankara Education and Research Hospital · Ankara, Turkey (Türkiye)
  • Hospital Sant Joan de Deu · Esplugues de Llobregat, Spain
across 3 updates, Oct 13, 2026 – Nov 12, 2026
Show all 3 updates
  1. Nov 12, 2026
    1 site added — first site in Spain
    Show site
    • Hospital Sant Joan de Deu · Esplugues de Llobregat, Spain
    + 1 other change: verification date
  2. Oct 22, 2026
    1 site added
    Show site
    • Ankara Education and Research Hospital · Ankara, Turkey (Türkiye)
  3. Oct 13, 2026
    1 site added — first site in Turkey (Türkiye)
    Show site
    • Erciyes University · Kayseri, Turkey (Türkiye)
    + 2 other changes: verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07220772
Responsible party
Sponsor
First posted
Oct 24, 2025
Start date
Feb 9, 2026
Primary completion
Jun 18, 2027 (estimated)
Completion
Apr 21, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mibavademab

Start the discussion